Dendreon Corp fka DNDNQ

[stuck_holder]

Interview with Dr. Petrylak re: his Sipuleucel-T Chemo Symposium presentation (first 4 minutes of the file)

http://www.asco.org/pc/mediafiles/ajoia/2006/11/0611151stASCOpodcast.mp3

from his responses, it seems to me he is already looking ahead to pre-clinical models to design combo studies to figure out the best way to integrate/sequence Provenge & docetaxel treatments in order to obtain the optimal interaction between the two, essentially assuming approval, until the interviewer asks whether the "provocative" data needs to be looked at prospectively - i.e., Sipuleucel-T needs to be approved first, where the good Doctor seems to catch himself, and acknowledges it needs FDA approval first before looking at "a lot of work to do in the future"